Group items tagged

Starts shipping December 2016. Preorder now, and be the first to grab your copy. Need to boost your HCPCS coding skills for services, supplies, drugs, and durable medical equipment (DME)? Want to stop claim denials and receive the reimbursement you deserve?

Smoking Cessation Guidelines Reviews & Guide is easiest way to quit smoking addiction for those of you who will be or are learning to stop smoking addi

How chemotherapy takes place? Depending on type of cancer and period of cancer, it stops cancer cells ability of damage and more to divide. Oftenly drugs are used and different for different person. This is systematic therapy also affect your entire body.

Emerging and advancing medical technologies reached new heights in 2020 and show no signs of stopping marching into 2021. The COVID crisis has led to many innovations and advancements, and it seems this trend isn't over yet. Full Article: https://www.hospitalrecruiting.com/blog/7111/advancing-medical-technology-2021/?fbclid=IwAR0cWYQgV0I2_7aut2mPwQn24fcrIEAveGkrWV2JYy9ee10F5zB_nnXUfJk #physician #EmergingTech #emergingtechnologies #medicaltechnology

At times, vaccines can become a controversial topic. People often have strong opinions about where protecting society as a whole stops and an individual's rights start. With COVID-19 in the news and the potential for a vaccine, the topic is not going away any time soon. If you're a healthcare worker, vaccine requirements are likely not new to you. But can employers mandate vaccines, and can you refuse? Keep reading to find out more.

Supply of all Champix products, used for smoking cessation, will remain out of stock until further notice from the Medicines and Healthcare products Regulatory Agency (MHRA). The announcement follows a medicine recall order initiated by the MHRA for "all strengths of Champix® tablets" on October 14, 2021 at pharmacy and wholesaler level. Pfizer, the sole supplier of Champix tablets, stopped the distribution of 0.5mg and 1mg tablets in early June 2021. The company is currently unable to confirm when supplies will resume amid global regulatory investigations relating to the presence of nitrosamine impurities above the Pfizer's acceptable level of daily intake in several lots.

The Medicines and Healthcare products Regulatory Agency (MHRA) has advised healthcare professionals to stop supplying a specific batch of Paroxetine 40mg Film Coated Tablets immediately. Crescent Pharma Limited is recalling a specific batch of Paroxetine 40mg Film Coated Tablets as a precautionary measure due to out of specification results for dissolution during routine stability testing. "Quarantine all remaining stock of the said batch and return it to your supplier, using your supplier's approved process," said MHRA. The agency alerted the patients that this is a precautionary Pharmacy and Wholesaler level recall, therefore no further action is required by patients.

In its first, the National Institute for Health and Care Excellence (NICE) has recommended the use of Pre Exposure Prophylaxis (PrEP) to treat people at the highest risk of catching HIV. The announcement comes along with a consultation on draft guideline by NICE on reducing sexually transmitted infections. NICE's recommendation is backed up by the government's HIV Action Plan to hit zero new transmissions of HIV by 2030. The pill prevents HIV by stopping the virus from crossing into the healthy cells and replicating. According to the UK PROUD study, PrEP reduced the risk of HIV infection by 86 per cent for men who have sex with men. However, people taking the pill must also get regular HIV testing and STI screening done every three months.

The new NHS chief executive Amanda Pritchard acknowledged and thanked health service staff and volunteers for their "extraordinary team effort" while the country fights Omicron. Pritchard, who took up the post in July, praised the efforts of doctors, nurses, therapists, porters and other staff who have worked hard to recover services impacted by the Covid-19 pandemic. In her first Christmas message as the NHS chief, she praised all those involved in the NHS Covid vaccination programme which delivered more than 7 million jabs, including boosters, in the last 10 days alone. She said: "We've had another extraordinary 12 months. "From January when hospitals admitted 100,000 patients with Covid in a single month, while also delivering the world-class NHS covid vaccination programme; to receiving the George Cross during the summer, marked by a service at St Paul's, pulling out all the stops to make progress on recovering backlogs of care; and now facing the uncertainty of Omicron and winter pressures.

A new study has shown that Covid-19 can spread between unmasked people at a distance of more than two metres even outdoors. A team of engineers from the University of Cambridge used computer modelling to quantify how droplets spread when people cough. They found that the two-metre rule was arbitrary and that social distancing alone was not enough to stop the spread of the virus. The team also found that individual coughs vary widely, and that the 'safe' distance could have been set at anywhere between one to three or more metres. The results, published in the journal Physics of Fluids, suggest that social distancing is not an effective mitigation measure on its own, and underline the importance of vaccination, ventilation and masks.

Two new medications which fight drug-resistant superbugs could soon become available to NHS patients in England after the National Institute for Health and Care Excellence (NICE) said they offered value for money. NICE said Cefiderocol and ceftazidime-avibactam will be the first antimicrobial drugs to be made available as part of a subscription-style payment model that incentivises research and development of antimicrobials by testing new approaches to evaluating and paying for them. As part of part of a project with the NHS and the Department of Health and Social Care, the new payment model is designed to address the growing threat posed by antimicrobial resistance - a serious global problem - which develops when the pathogens that cause infection evolve to make antibiotics and other antimicrobial drugs less effective or stop them from working altogether.

NHS cancer check has set a new record, despite pressures on hospitals due to Covid-19, the number of people being treated for the cancer remained higher than before the pandemic, revealed NHS. Over the last 12 months almost three million people were referred for cancer checks which is up by over a tenth on the 2.4 million people referred before the pandemic. "Even at the peak of the Omicron wave, referrals for suspected cancer were at 116 per cent of pre-pandemic levels with around 11,000 people getting checked every day over the last year," said NHS. In order to meet increasing demand for cancer checks, NHS services across the country are expanding their diagnostic capabilities through one stop shops for tests, mobile clinics and cancer symptom hotlines, ensuring people are diagnosed and treated as early as possible to give them a much better chance of beating the disease. More than 30,000 people every month are being invited for lung cancer checks through NHS mobile trucks visiting at risk communities across the country, as part of the biggest programme to improve early lung cancer diagnosis in health service history.

The Medicines and Healthcare products Regulatory Agency (MHRA) has recalled Labetalol 200mg tablets (Tillomed Laboratories Ltd) directed to pharmacies and wholesalers. Manufacturer, Tillomed Laboratories is recalling one batch of Labetalol 200mg tablets due to an error on the foil blister packaging. The incorrect aluminium foil blister packaging states Labetalol 100mg tablets, however it should be labelled as Labetalol 200mg Tablets. This error has occurred at the primary packing operation. Tillomed Laboratories Limited has confirmed the actual tablet contained in the blister is Labetalol 200mg Tablets, which is the strength stated on the outer carton. This error is limited to the packaging of the batch with 100mg aluminium foil blister and does not impact the lot (batch) number or expiry as printed on the outer carton and aluminium foil blister. Healthcare professionals has been advised to stop supplying the batches immediately. Quarantine all remaining stock and return it to supplier using supplier's approved process.

The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a class 2 medicines recall for Sabril 500 mg film-coated tablets & Sabril 500 mg granules for oral solution. Sanofi UK has recalled the batches of Sabril tablets and Sabril granules as a precautionary measure due to the detection of traces of tiapride in the batches of the source material of the manufacturer for vigabatrin. Sabril (vigabatrin) is indicated for adjunctive treatment of focal seizures with or without secondary generalisation not satisfactorily controlled with other antiepileptics (under expert supervision) and monotherapy in the treatment of infantile spasms (West's syndrome). All patients are advised not to discontinue Sabril tablets or Sabril granules without consulting with their prescriber. The risks of suddenly stopping medication for seizures/epilepsy is higher than the potential risk presented by the presence of tiapride. Sanofi UK have confirmed to DHSC that no other batches are impacted, and other stock remains available.

Those of us who work in community pharmacy know there is a workforce crisis created in large measure by PCNs actively recruiting pharmacists and pharmacy technicians from our sector. It is welcome, if long overdue, that this has now been officially acknowledged in a report commissioned by the English Health Secretary. PCN hiring 'exacerbates pharmacist shortage' says DH-commissioned report, which states such recruitment has "on occasion exacerbated the problem of a general shortage of pharmacists" which has compounded "the problem of community pharmacy closures." We have been telling the government this for years only to be told "problem? What problem?"- but now that Steve Barclay has his own official report sitting on his desk, he and NHSE cannot continue in denial mode. The facts are there for all to see. Time to act. No more dithering, delay or indifference. You asked if there was a problem and you have been told there is. In the absence of a holistic workforce strategy and cross-sector career pathways, PCNs poaching from community pharmacy is a zero sum game adding nothing to improving patient care.

Adults who are overweight or obese and have type 2 diabetes or prediabetes are at a higher risk of developing severe health issues, according to authors of a recent study. Experts. however, disagree on the best dietary regimens and supportive measures to suggest. The latest study was published in the journal 'The Annals of Family Medicine'. In the findings, researchers used a 2×2 diet-by-support factorial design to randomise 94 adults with the aforementioned conditions, contrasting a very low-carbohydrate (VLC) or ketogenic diet with a Dietary Approaches to Stop Hypertension (DASH) diet. They also determined the outcomes of interventions that included and excluded additional support practices like mindful eating, effective emotion regulation, social support, and cooking instruction. Using intent-to-treat analyses, the VLC diet led to greater improvement in estimated mean systolic blood pressure (SBP; -9.8 mmHg vs. -5.2 mmHg, P =.046), greater improvement in glycosylated haemoglobin (HbA1c; -.4 per cent vs. -.1 per cent, P = 0.034), and greater improvement in weight (-19.14 lbs vs. -10.33 lbs, P = 0.0003), compared to the DASH diet. The addition of extra support did not have a statistically significant effect on outcomes.

Community pharmacy bodies have said that the current crippling financial pressures and severe staff shortages will limit the sector from fully supporting the new health secretary's ambition to improve patient care in England. Thérèse Coffey announced her plans on Thursday (September 22) which would be looking to reduce the country's reliance on general practice by expanding the range of services available from community pharmacies and allowing pharmacists more "prescribing powers". "Pharmacists will be able to manage and supply more medicines, without a prescription from a GP. We will look to go further on enabling pharmacists with more prescribing powers and making more simple diagnostic tests available in community pharmacy," she said in her foreword to Our Plan for Patients. However, the National Pharmacy Association has lamented that the plan stops short of promising any fresh funding for community pharmacies to deliver patient care and develop clinical services. NPA vice-chair, Nick Kaye, said: "The life is being choked out of independent pharmacy businesses by the continuation of a fundamentally under-resourced contract in England.

harac, an NHS-integrated one-stop platform for independent community pharmacies, and the National Pharmacy Association (NPA) have announced their long-term partnership to allow pharmacies to deliver the broad range of services needed to support the public. The NPA and Charac will collaborate with members of the NPA and beyond to accelerate the necessary digital transition of independent community pharmacies, particularly given their importance to poorer communities and less advantaged individuals at high risk due to potential pharmacy closures. The partnership is part of the NPA's efforts to improve the online presence of community pharmacies, including patient application, online booking, website design, and a delivery service. With Charac similarly dedicated to bettering digital interaction with patients, the new joint ecosystem will provide pharmacies with the necessary funding and cutting-edge technology to aid delivery of primary care.

The Medicines and Healthcare products Regulatory Agency (MHRA) has asked the pharmacies and wholesalers to stop supplying and quarantine all remaining stock of Dr Reddy's Laboratories (UK)'s Lacidipine 4 mg Film-Coated tablets. The company has recalled two batches of Lacidipine 4 mg Film-Coated tablets as a precautionary measure due to the presence of an unknown solvent-like odour. MHRA said: "The tablets are normally odourless. However, in the affected batches, a solvent-like odour is present when the individual blisters are opened. Additionally, some patient complaints have noted that the tablets have an unusual taste. The investigation to determine the root cause and to identify and quantify the odour is ongoing. "The issue is confined to batches B2202043 and B2202044 only. Other batches of Lacidipine 4 mg Film-Coated tablets marketed by Dr Reddy's Laboratories (UK) are not affected."